Adoptive T Cell Therapy Using Educated T Cells Generated By the Sequential Stimulation With Dc/Tumor Fusion Cells and Anti-CD3/CD28
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Corrine Zarwan(Beth Israel Deaconess Medical Center), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Zhiyou Wu(Dana-Farber Cancer Institute), Kristen E. Stevenson(Dana-Farber Cancer Institute), Heidi Mills(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), Thea M. Friedman(Hackensack University Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k